Business
Atossa is a clinical-stage biopharma company developing proprietary medicines in oncology, with a focus on breast cancer and other breast conditions.
Atossa had no revenue, net loss widened to $34.8M, FCF fell to -$29.8M, and equity fell 44.9%.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage breast cancer therapeuticsNote
- Revenue — No revenueWatch
- Losses — Net loss widened 36.3%Watch
- Cash — FCF was -$29.8MWatch
- Balance sheet — Equity fell 44.9%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Forensic screen unavailableNote
Leadership changes
From ATOSSA THERAPEUTICS, INC.'s own filings, the day they're filed.
- Heather Rees · Chief Financial Officer · appointmenteff. 2024-06-27
- Tessa Cigler · director · appointmenteff. 2024-03-09
- Jonathan Finn · directors · appointmenteff. 2023-11-09
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-08
- 8-K · Company announcement2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ATOSSA THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.